Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

ONCOlogic patient profiling and personalized treatment through SMART bedside diagnostics

Objetivo

The advent of personalized cancer care demands for distributed diagnostic solutions to support clinical decisions and selection of the best therapeutic regimen. Supportive information can be obtained by analyzing the response of patient’s tissue to various treatment options. A specific opportunity arises in the field of cellular analysis, where the ex-vivo assessment of drug efficacy performed through drug response assays represents a powerful tool and, at the same time, a challenge due to the difficulty of maintaining in-vitro conditions that closely resemble in-vivo cell response.

CellPly developed a novel in-vitro diagnostic (IVD) product to define cell response to anti-cancer drug treatment through integrated drug response analyses. Oncosmart platform includes a smart consumable, integrating a hybrid polymer/flexible-PCB micro-technology, an analytical instrument and diagnostic software.

After patient’s tissue sampling, an automated process will carry out sample preparation, precise drug delivery and monitoring of cell response through time-lapse imaging. Cancer patients will benefit from more personalized cancer therapies, while the public health systems will reduce overall analysis and hospitalization costs and better allocate resources dedicated to cancer therapies.

The Phase 1 project will set up the a quality-certified manufacturing chain and plan the validation of the platform in clinical setting in the field of acute leukemia; regulatory pathways to comply with CE-IVD and to seek reimbursement will be assessed; the commercialization strategy and associated business model(s) will be elaborated.

Convocatoria de propuestas

H2020-SMEInst-2016-2017

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SMEINST-1-2016-2017

Régimen de financiación

SME-1 - SME instrument phase 1

Coordinador

CELLPLY SRL
Aportación neta de la UEn
€ 50 000,00
Dirección
VIA FONDAZZA 53
40125 Bologna
Italia

Ver en el mapa

Pyme

Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.

Región
Nord-Est Emilia-Romagna Bologna
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 71 429,00